S&P Futures
5,898.75 +2.25 (+0.04%) Dow Futures
43,411.00 -157.00 (-0.36%) Nasdaq Futures
20,571.00 +77.25 (+0.38%) Russell 2000 Futures
2,319.50 +5.90 (+0.26%) Crude Oil
67.32 +0.30 (+0.45%) Gold
2,597.30 +27.20 (+1.06%)
After hours:
| Previous Close | 2.7000 |
| Open | 2.7350 |
| Bid | 2.4900 x 100 |
| Ask | 2.5800 x 100 |
| Day's Range | 2.4800 - 2.7350 |
| 52 Week Range | 2.4500 - 16.2400 |
| Volume | |
| Avg. Volume | 691,300 |
| Market Cap | 178.539M |
| Beta (5Y Monthly) | 0.87 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.8300 |
| Earnings Date | Nov 07, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15.83 |
GlobeNewswireNkarta to Participate in an Upcoming Investor Conference
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference: Stifel 2024 Healthcare ConferenceNovember 19, 202410:55 a.m. ET – fireside chat A simultaneous webcast of the event will be available on the Investors section of Nkarta’s website, www.nkartatx.com, and a replay will be archived on the website for app
- GlobeNewswire
Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights
First patient dosed in each of Ntrust-1 and investigator-sponsored clinical trial (IST) of NKX019; enrollment ongoing in both studiesEnrollment in Ntrust-2 expected to initiate by year-end 2024 Preliminary clinical data from Ntrust-1 and Ntrust-2 clinical trials planned for 2025No further NKX019 development in lymphoma planned Platform prioritized to focus on advancement of NKX019 for multiple autoimmune diseases Cash balance of $405.3 million on September 30, 2024, including cash, cash equivale
